A national registry for thermal ablation treatment for breast cancer is under consideration by the FDA. The agency opened a six-month public comment period this week on the proposed registry, which would compile information on all thermal ablation devices and therapies for small carcinomas.
A national registry for thermal ablation treatment for breast cancer is under consideration by the FDA. The agency opened a six-month public comment period this week on the proposed registry, which would compile information on all thermal ablation devices and therapies for small carcinomas. The FDA is looking to determine if a registry could be used to standardize trials for different thermal ablation devices, such as focused ultrasound, cryoablation, and radiofrequency ablation. The registry would also lay out standard protocols for tumor selection, biopsy techniques, pathology studies, image guidance, and postablation assessment."Unfortunately, the lack of uniformity among different feasibility study protocols has resulted in various study results that cannot be easily compared," said an announcement in the May 28 Federal Registry. "The purpose of this critical path effort is to motivate the breast cancer ablation industry to standardize its feasibility study protocols so that data emerging are comparable in all respects."Comments must be submitted either through an electronic form or by mail. Comments will not be accepted by e-mail, the FDA announcement said.Click here to submit comments online. Mailed comments should be sent to: Division of Dockets Management (HFA-305), FDA5630 Fishers Lane, Room 1061Rockville, MD 20852The public comment period will close on November 24, 2008.Click here to learn more about the proposed registry, which will be administered through the FDA's Center for Devices and Radiological Health.For more information from the Diagnostic Imaging archives:Focused ultrasound spells a year of fibroid pain reliefCryoablation proves its palliative power in soft tissue, bone tumors
This is one of many ads taken out by the American College of Radiology for its "Face of Radiology" campaign. The effort is an attempt to improve public perception of radiologists.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.